Evaluation of immunization with purine salvation pathway recombinant enzymes in Schistosoma mansoni worms and eggs in murine schistosomiasis

Abstract

According to the World Health Organization (WHO), on tropical and subtropical areas, schistosomiasis is the second parasitic disease of greater prevalence, in terms of morbidity and mortality, surpassed only by malaria. The Praziquantel (PZQ) is used for the treatment of this disease. However, reports of resistant strains reinforce the need to develop a new schistosomicidal drug. The infection by the parasite induces an inflammatory reaction of long duration due to the presence of adult worms living in the mesenteric venous system. The parasite lays eggs in small vessels of the submucosa of the intestines. These eggs are transported by the blood flow to the liver and they cause a granulomatous inflammatory reaction. A new approach can be held by the study of the following Schistosoma mansoni enzymes: purine nucleoside phosphorilase 1 (PNP), hypoxanthine guanine phosphoribosyltransferase (HGPRT) and adenylate kinase (ADK). The parasite, incapable of synthetizing purine nucleotides through the de novo pathway, has multiple mechanisms to incorporate purine bases through the purine salvage pathway. In our results, we suggest that the immunization in Balb/c mice with the mentioned recombinant enzymes was capable of inducing a specific immune response, favoring the reduction of both the parasite load and number of eggs per gram of feces. The acquired data show that these enzymes can be considered as new targets to immunotherapy against schistosomiasis mansoni.CNPqFAPES